drugset / Trial / NCT00744640
Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma
Phase 1/2
Completed
46 enrolled
University Hospital, Basel, Switzerland
Roche Pharma AG · collabSanofi · collabSwiss Cancer League · collabSwiss National Science Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
Gemcitabine is the mainstay of palliative chemotherapy for patients with advanced pancreatic cancer (APC). Recent randomized trials have shown increased clinical benefit with the addition of oxaliplatin and prolonged median survival with the addition of capecitabine to gemcitabine. Gemcitabine, capecitabine and oxaliplatin are 3 newer, well tolerated anticancer drugs with mild and non-overlapping toxicity profiles. We therefore propose a dose-finding and safety study of the triple combination gemcitabine, capecitabine and oxaliplatin in patients with APC (Phase I part), followed by a phase II part to assess preliminary efficacy of this triple combination.
Timeline
- Start
- 2005-10
- Primary completion
- 2009-02
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |